Skip to content
WeighLab
Grade C

StaveMD Review: Price, Pros & Cons

By The WeighLab Bench, Tools & Data Desk

StaveMD lists compounded semaglutide, as a weekly shot or a dissolving tablet, from $199 a month and tirzepatide from $249, with a refund on any month whose medication hasn't been ordered yet.

Visit StaveMD Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$199/moStarting price, compounded injection or dissolving tablet
Tirzepatide
$249/moStarting price, compounded
Coverage
All 50 states and D.C.
Brand-name
Compounded only

Semaglutide · modeled / year

$2,388

Tirzepatide · modeled / year

$2,988

The Index scorecard

StaveMD scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month60/100
Price Transparency84/100
Nationwide Access86/100
Formulation Options77/100
Clinical Oversight73/100
Contract Flexibility91/100

Where the value is

  • Cancel any time from your account with no phone call or notice period, and request a refund for any month whose medication hasn't been ordered
  • Offers compounded semaglutide as a weekly injection or a daily dissolving tablet, plus tirzepatide and a lower-dose microdose program from $179 a month
  • Names its pharmacies, led by Red Rock Compounding Pharmacy in Utah, and its medical group, OpenLoop Healthcare Partners
  • Says it serves all 50 states and Washington, D.C., with free discreet shipping and HSA/FSA eligibility
  • No membership fee, and every program includes provider visits, medication and shipping

The tradeoffs

  • Every price is a "starting from" figure; the site says longer programs cost less per month and are billed upfront but doesn't print the price of each plan length
  • The banner's "Start for $179/mo" is the microdose program, not the standard semaglutide or tirzepatide dose
  • "Trusted by millions" and "3,000,000+ members" are totals for its telehealth partner's whole network, as a footnote admits, not StaveMD patients
  • The homepage names one pharmacy while the terms list four that may fill your prescription
  • Compounded semaglutide and tirzepatide are not FDA-approved products

The bottom line

Best for: Shoppers who want an oral or injectable compounded GLP-1 with easy cancellation and are willing to confirm the plan price at checkout. StaveMD lists compounded semaglutide, as a weekly shot or a dissolving tablet, from $199 a month and tirzepatide from $249, with a refund on any month whose medication hasn't been ordered yet.

For comparison, read our review of CoreAge Rx, one of our partners. Partners are listed first on our leaderboard; every provider is scored on the same six factors.

Other programs to compare with StaveMD

These are partners: we may earn a commission if you sign up, at no cost to you.

  • MyDrHankPartner

    Semaglutide from $249/mo · tirzepatide from $349/mo

    Every price this site advertises is a twelve-month prepay rate — its price display returns the cheapest term by design — so the real month-to-month cost is $249-$349, not the "from $171" on the page.

  • CollectivePartner

    Semaglutide from $59/mo · tirzepatide from $69/mo

    Collective sells compounded semaglutide at $59 and tirzepatide at $69 a month, both genuinely medication prices, on top of a $199 annual membership that is required, auto-renewing and not refundable.

  • LttlPartner

    Semaglutide from $99/mo · tirzepatide from $149/mo

    Lttl charges $99 every four weeks for compounded semaglutide and $149 for tirzepatide on a cancel-anytime auto-refill, with small discounts for longer supplies.

Compare with other providers

The providers whose Cost-Efficiency Index scores sit closest to StaveMD's. See the alternatives to StaveMD.

The 22 programs nearest this one

Pricing, states and verification reflect StaveMD's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on StaveMD's site. Not medical advice; see our disclosure.

← Back to the value leaderboard